Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15281MR)

This product GTTS-WQ15281MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15281MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1383MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ10118MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ15872MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ820MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ9212MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ1166MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ10181MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ3177MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW